31% objective response rate (ORR) and median duration of response (mDOR) at 36.5 months median study follow-up in Study C-144-01 (Cohorts 2 and 4) not reached
42% of the responses lasted longer than 24 months
SITC Update and KOL Panel Webcast Thursday, November 10 at 4:30 p.m. ET
SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. IOVAa late-stage biotechnology company developing novel T-cell-based cancer immunotherapies (tumor-infiltrating lymphocytes, TIL and peripheral blood lymphocytes, PBL), today announced updated clinical data for Lifileucel in advanced melanoma during a rapid oral presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)..
Amod Sarnaik, MD, Professor of Cutaneous Oncology and Immunology at the H. Lee Moffitt Cancer Center, presenting author and principal investigator of the C-144-01 study, stated, “We are pleased to present the comprehensive clinical data for C-144 – 01 investigators. The study demonstrated a robust and clinically meaningful response rate and long-term durability after a single treatment. The patients in this study were difficult to treat and lacked therapies approved by the current standard of care. We hope to offer Lifileucel to many more patients after initial progression on immune checkpoint inhibitors.”
That oral lecture for the C-144-01 study included efficacy data from 153 patients with advanced melanoma enrolled in Cohort 2 (n=66) and Cohort 4 (n=87) with a median follow-up of 36.5…
